



# Targeting

## Chondrosarcoma

**IP-926-04: A Safety and Efficacy Study of  
Patients With Metastatic or Locally Advanced  
(Unresectable) Chondrosarcoma**

*IP-926 is an investigational drug currently being studied in clinical trials and is not yet approved by the U.S. Food and Drug Administration or the regulatory agency of any other country.*

## WHAT IS CHONDROSARCOMA?

Chondrosarcoma is a rare, debilitating cancer that affects the cartilage. Cartilage is the tissue that covers the ends of bones in joints. Chondrosarcoma tends to affect middle-aged and older adults and increases in incidence with age. However, it can also occur at younger ages.

Chondrosarcoma can occur in any bone in the body. The symptoms associated with chondrosarcoma depend upon the size and location of the cancer. Symptoms usually appear when the cancer grows large enough to cause swelling or pain. Sometimes, the affected bone may break.

Localized chondrosarcoma can often be cured by surgery, which is the standard therapy for this disease. However, if chondrosarcoma spreads to other areas of the body and can no longer be removed by surgery, there are no effective treatment options. Chondrosarcomas do not usually respond well to chemotherapy or radiation.





## **TARGETING THE HEDGEHOG PATHWAY: A POTENTIAL NEW WAY TO TREAT CHONDROSARCOMA**

Normal cell growth and development is controlled by cellular pathways made up of groups of proteins. The Hedgehog pathway is a cellular pathway that is active in the human body early in life when bones and growth plates increase in length. Research suggests that this pathway may play a key role in how and why certain types of cancer develop and grow. In a healthy adult, the Hedgehog pathway is inactive or “turned off” in most cells. In people with some cancers, such as chondrosarcoma, the Hedgehog pathway is turned on and may promote cancer growth and survival. Research has shown that blocking the pathway may delay or prevent the growth of chondrosarcoma.

## WHAT IS IPI-926?

IPI-926 is an experimental medicine being tested in chondrosarcoma and other types of cancer. IPI-926 blocks the function of a key protein in the Hedgehog Pathway called "Smoothened." Blocking "Smoothened" may disrupt the growth and spread of cancer cells. IPI-926 is being tested alone and in combination with other standard cancer treatments. One of these clinical trials is currently testing IPI-926 as a potential treatment for advanced chondrosarcoma in patients for whom surgery is no longer an option.

## WHAT ARE CANCER CLINICAL TRIALS?

A cancer clinical trial is designed to test the potential benefits or risks of new or experimental treatment approaches. There are four phases of clinical trials for people with cancer:

### Phases of Cancer Clinical Trials

Phase of Trial	Purpose of Trial
Phase 1	A drug is tested in a small group of people with many different types of cancer. In this phase, the drug's overall safety is studied, the most common side effects are identified, and a dose is selected for future testing.
Phase 2	A drug is tested in specific types of cancer to further study its safety and beneficial effects (efficacy).
Phase 3	A drug is tested in a larger group of people with a specific type of cancer to determine how safe and efficacious it is compared to currently approved treatments.
Phase 4	Once a new drug is approved by the U.S. Food and Drug Administration, additional trials help physicians learn more about how the new drug may be used in specific cancers.

## WHAT IS THE IPI-926-04 CHONDROSARCOMA TRIAL?

IPI-926-04 is a phase 2 trial of IPI-926 being performed to determine the potential effectiveness and safety of IPI-926 capsules given once daily compared to placebo capsules (sugar pills), in people who have advanced or metastatic chondrosarcoma that can no longer be treated by surgery. People who are assigned to receive placebo capsules at the beginning of the trial will have the option to receive IPI-926 capsules once their disease progresses. This Phase 2 trial will include approximately 100 patients from 15 countries around the world.

## HOW CAN I PARTICIPATE IN THE IPI-926-04 TRIAL?

First, you should speak with your physician to determine if the IPI-926 trial in chondrosarcoma is right for you. As with any clinical trial evaluating a new or experimental treatment, people who choose to participate have to meet certain criteria related to age, previous and current treatments, and other health-related conditions in order to qualify. Your doctor or nurse will review the trial criteria with you in detail; however, initial criteria to participate will include:

- At least 18 years of age
- Confirmed metastatic or locally advanced chondrosarcoma, which can no longer be treated by surgery
- Confirmed radiographic disease progression within a 6 month time period prior to study participation

For a more complete list of participation criteria, please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and enter the following number into the search box: **01310816**.

## ADDITIONAL RESOURCES

- American Cancer Society ([www.cancer.org](http://www.cancer.org))
- Sarcoma Alliance ([www.sarcomaalliance.org](http://www.sarcomaalliance.org))
- Sarcoma Foundation of America ([www.curesarcoma.org](http://www.curesarcoma.org))

## ABOUT INFINITY PHARMACEUTICALS

Infinity is an innovative drug discovery and development company based in Cambridge, Massachusetts. Infinity's goal is to discover, develop and deliver to patients best-in-class medicines for difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways.



For more information on Infinity, please visit [www.infi.com](http://www.infi.com).

Infinity Pharmaceuticals

780 Memorial Drive | Cambridge, MA 02139

t: 617-453-1000 | f: 617-453-1001 | e-mail: [info@infi.com](mailto:info@infi.com)